<DOC>
	<DOCNO>NCT00273442</DOCNO>
	<brief_summary>To assess safety efficacy cohort patient switch dorzolamide/timolol maleate fix combination insufficiently control latanoprost monotherapy .</brief_summary>
	<brief_title>Assessing Cosopt Switch Patients</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Exfoliation Syndrome</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Dorzolamide</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>adult clinical diagnosis POAG , pigmentdispersion exfoliation glaucoma ocular hypertension IOP latanoprost must 31 mm Hg less eye , 21 31 mm Hg inclusive least one eye 08:00 AM visual acuity 20/200 good eye contraindication study drug anticipate change systemic hypotensive therapy trial use corticosteroid route three month immediately prior Visit 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>